Aptose Biosciences Inc. (TSX: APS)

Aptose Biosciences Inc.
  • 0.0 (0)
  • Investing

Podcast with news and updates from Aptose Biosciences (NASDAQ: APTO, TSX: APS), a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways.

Episodes

  1. 05/14/2020

    William Rice, Aptose Biosciences: Clinical Programs in the Works

    William Rice, Aptose Biosciences: Clinical Programs in the Works

  2. 05/30/2018

    William Rice, CEO and Greg Chow, CFO of Aptose Biosciences Molecule Expected to Return to Clinic

    William Rice, CEO and Greg Chow, CFO of Aptose Biosciences Molecule Expected to Return to Clinic

  • 2 Episodes

About

Podcast with news and updates from Aptose Biosciences (NASDAQ: APTO, TSX: APS), a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways.

Information

  • Creator
    Aptose Biosciences Inc.
  • Episodes
    2
  • Rating
    Clean
  • Copyright
    © Aptose Biosciences Inc.